ALLEGRO-2b/3 Ritlecitinib Sustained Response

Published: 9 October 2024| Version 2 | DOI: 10.17632/y5zfkt73s9.2
Contributor:
Liza Takiya

Description

Supplementary Data, plain language summary, and video abstract to accompany Piliang M, et al. Sustained hair regrowth with continued ritlecitinib treatment through Week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b/3 trial.

Files

Categories

Alopecia, Management of Alopecia Symptom, Hair Loss, Alopecia Areata, Janus Kinase

Licence